Oric Pharmaceuticals Inc
$ 13.50
4.41%
07 Aug - close price
- Market Cap 1,399,311,000 USD
- Current Price $ 13.50
- High / Low $ 13.50 / 12.78
- Stock P/E N/A
- Book Value 4.02
- EPS -1.36
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -0.40 %
- 52 Week High 14.93
- 52 Week Low 7.23
About
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers. The company is headquartered in South San Francisco, California.
Analyst Target Price
$20.85
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-03 | 2026-05-04 | 2026-02-23 | 2025-11-13 | 2025-08-12 | 2025-05-05 | 2025-02-18 | 2024-11-12 | 2024-08-12 | 2024-05-06 | 2024-03-11 | 2023-11-06 |
| Reported EPS | -0.38 | -0.34 | -0.3 | -0.33 | -0.47 | -0.42 | -0.51 | -0.49 | -0.45 | -0.37 | -0.49 | -0.44 |
| Estimated EPS | -0.36 | -0.32 | -0.3669 | -0.4 | -0.44 | -0.5 | -0.5084 | -0.47 | -0.41 | -0.43 | -0.49 | -0.46 |
| Surprise | -0.02 | -0.02 | 0.0669 | 0.07 | -0.03 | 0.08 | -0.0016 | -0.02 | -0.04 | 0.06 | 0 | 0.02 |
| Surprise Percentage | -5.5556% | -6.25% | 18.2339% | 17.5% | -6.8182% | 16% | -0.3147% | -4.2553% | -9.7561% | 13.9535% | 0% | 4.3478% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ORIC
2026-08-05 19:12:17
Evercore ISI analyst Cory Kasimov has maintained a Buy rating on Oric Pharmaceuticals (ORIC) with a price target of $25.00. Kasimov has a strong track record in the Healthcare sector, and Oric Pharmaceuticals holds a consensus "Strong Buy" rating from analysts. The company recently reported a quarterly GAAP net loss of $41.49 million for the quarter ending June 30.
2026-08-05 04:09:28
ORIC Pharmaceuticals reported widening net losses in Q2 and the first half of 2026, reaching US$41.49 million and US$77.26 million respectively. Despite this, the company saw improved basic and diluted loss per share due to a larger share count. The article suggests that equity remains the primary funding mechanism for the high-risk biotech firm, with clinical trial execution being the near-term catalyst.
2026-08-04 19:40:55
ORIC Pharmaceuticals reported widening net losses for Q2 and H1 2026, reaching US$41.49 million and US$77.26 million respectively. Despite this, basic and diluted loss per share improved to US$0.38 and US$0.72 for the same periods, primarily due to a larger share count. The company's investment narrative remains that of a high-risk biotech heavily reliant on its oncology pipeline, with future dilution and clinical trial success being key factors for investors.
2026-08-04 18:09:28
Oric Pharmaceuticals (NASDAQ:ORIC) saw its shares rise by 12.3% in midday trading on Tuesday, despite a significant drop in trading volume and a recent earnings miss. The company maintains a "Moderate Buy" consensus rating from analysts, with a target price of $19.27, and institutional investors hold a substantial 95.05% of its stock.
2026-08-04 17:09:29
Traders purchased a significantly high volume of put options on Oric Pharmaceuticals (NASDAQ:ORIC), indicating bearish sentiment or a desire for downside protection. This activity occurred despite the company's shares rising and analysts maintaining a "Moderate Buy" consensus rating with an average target price of $19.27. Institutional investors hold a substantial portion of the company's stock.
2026-08-04 07:40:05
ORIC Pharmaceuticals reported its Q2 2026 financial results, highlighting the initiation of the global Phase 3 Himalayas-1 trial for rinzimetostat in metastatic castration-resistant prostate cancer (mCRPC), which is expected to enroll approximately 600 patients. The company also announced a collaboration with Bayer for the trial and stated that its cash and investments of $387.6 million are expected to fund operations into the second half of 2028. Despite a net loss of $41.5 million in Q2, ORIC emphasized its advancement into a diversified, late-stage oncology company.
